Differential gene expression between various tissues and developmental stages can be compared rapidly and efficiently using the RNA arbitrarily primed polymerase chain reaction (RAP) fingerprinting method that was developed in our laboratories. In RAP, a primer of arbitrary sequence primes both first and second strand cDNA synthesis. The mixture of products is PCR amplified and resolved electrophoretically, yielding highly reproducible fingerprints that are tissue-specific. Differences between fingerprints arise from differentially expressed genes. The method samples RNAs with little bias, allowing the identification of novel differentially regulated transcripts. One of the most exciting applications of RAP technology is to brain development. An understanding of spatial and developmental differences in gene expression during development is an important goal in understanding the normal function of the brain and its pathology. The RAP method allows the comparison of many RNA samples simultaneously and, therefore, is capable of detecting among a large sample of expressed genes those few that are expressed for only a brief period during brain development, are expressed in only one or a few areas of the brain, or are differentially expressed between normal brains and those with neurodegenerative disorders. Such genes are attractive candidates for further analysis by conventional strategies. We will identify and characterize such genes from the mouse brain in an international collaborative effort. A pilot study has already demonstrated the feasibility of this approach.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS033377-01
Application #
2272162
Study Section
Genome Study Section (GNM)
Project Start
1994-09-30
Project End
1995-09-29
Budget Start
1994-09-30
Budget End
1995-09-29
Support Year
1
Fiscal Year
1994
Total Cost
Indirect Cost
Name
California Institute of Biological Research
Department
Type
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Trenkle, T; Mathieu-Daude, F; Welsh, J et al. (1999) Reduced complexity probes for DNA arrays. Methods Enzymol 303:380-92
Vogt, T; Kroiss, M; McClelland, M et al. (1999) Deficiency of a novel retinoblastoma binding protein 2-homolog is a consistent feature of sporadic human melanoma skin cancer. Lab Invest 79:1615-27
Vogt, T; Stolz, W; Welsh, J et al. (1998) Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas. Clin Cancer Res 4:791-7
McClelland, M; Wilson, R K (1998) Comparison of sample sequences of the Salmonella typhi genome to the sequence of the complete Escherichia coli K-12 genome. Infect Immun 66:4305-12
Pesole, G; Liuni, S; Grillo, G et al. (1998) GeneUp: a program to select short PCR primer pairs that occur in multiple members of sequence lists. Biotechniques 25:112-7, 120-3
Mathieu-Daude, F; Welsh, J; Davis, C et al. (1998) Differentially expressed genes in the Trypanosoma brucei life cycle identified by RNA fingerprinting. Mol Biochem Parasitol 92:15-28
Schweitzer, B; Taylor, V; Welcher, A A et al. (1998) Neural membrane protein 35 (NMP35): a novel member of a gene family which is highly expressed in the adult nervous system. Mol Cell Neurosci 11:260-73
Trenkle, T; Welsh, J; Jung, B et al. (1998) Non-stoichiometric reduced complexity probes for cDNA arrays. Nucleic Acids Res 26:3883-91
Vogt, T M; Welsh, J; Stolz, W et al. (1997) RNA fingerprinting displays UVB-specific disruption of transcriptional control in human melanocytes. Cancer Res 57:3554-61
Vogt, T; Zipperer, K H; Vogt, A et al. (1997) p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin. Histopathology 30:57-63

Showing the most recent 10 out of 24 publications